BPC-157 vs MK-677 (Ibutamoren) vs TB-500
A three-way comparison to help you find the right peptide for your research goals.
BPC-157
Body Protection Compound-157 is a synthetic peptide derived from a protein found in human gastric juice. It has shown remarkable healing properties in research studies.
Full details →MK-677 (Ibutamoren)
MK-677, also known as Ibutamoren, is an orally active growth hormone secretagogue. Unlike peptides, it can be taken orally and has a long half-life, providing 24-hour GH elevation.
Full details →TB-500
Thymosin Beta-4 (TB-500) is a naturally occurring peptide present in almost all human and animal cells. It plays a crucial role in tissue repair and regeneration.
Full details →Side-by-Side Comparison
| Aspect | BPC-157 | MK-677 (Ibutamoren) | TB-500 |
|---|---|---|---|
| Dose Range | 250 mcg–500 mcg | 10 mg–25 mg | 2 mg–2.5 mg |
| Frequency | 2x daily | 1x daily | Less than daily |
| Cycle Length | 4–6 weeks | 8–24 weeks | 4–8 weeks |
| Route | subcutaneous | oral | subcutaneous |
| Mechanism | BPC-157 works through multiple pathways including upregulation of growth factor expression, nitric oxide system modulation, and promotion of angiogenesis. It enhances tendon-to-bone healing and supports the formation of new blood vessels. | Acts as a potent, selective agonist of the ghrelin receptor (GHS-R1a). Increases GH and IGF-1 levels without affecting cortisol. Mimics ghrelin's GH-releasing effects. | TB-500 promotes cell migration and differentiation, regulates actin (a cell-building protein), and reduces inflammation. It supports the formation of new blood vessels and wound healing. |
| Typical Dosage | Typical research dosages range from 250-500mcg administered 1-2 times daily. Both subcutaneous and oral administration have been studied. | Typical dosing: 10-25mg taken orally once daily. Often taken at night due to sleep benefits and appetite increase. | Research protocols typically use 2-2.5mg twice weekly during the loading phase, followed by maintenance dosing of 2mg every 2 weeks. |
| Administration | Can be administered subcutaneously near the injury site or systemically. Stable in gastric juice, making oral administration viable. | Oral administration (capsule or liquid). Can be taken with or without food. Long half-life allows once-daily dosing. | Administered via subcutaneous or intramuscular injection. Some protocols suggest injection near injury sites. |
| Side Effects | Generally well-tolerated in research. Some reports of mild nausea or dizziness at higher doses. | Increased appetite and water retention are most common. May cause lethargy, vivid dreams, and mild numbness. Can affect blood glucose and insulin sensitivity. | May cause temporary fatigue, headache, or localized irritation at injection sites. |
| Best For |
What They Have in Common
BPC-157, MK-677 (Ibutamoren), TB-500 are all commonly used for:
Key Differences
Unique to MK-677 (Ibutamoren):
Which Has Stronger Evidence?
- Muscle Growth: MK-677 (Ibutamoren) has stronger research support.
| Goal | BPC-157 | MK-677 (Ibutamoren) | TB-500 |
|---|---|---|---|
| Muscle Growth | medium | high | medium |
| Recovery & Healing | high | medium | high |
Key Studies
BPC-157
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
Current reviews in musculoskeletal medicine, 2025
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.
Alternative therapies in health and medicine, 2024
MK-677 (Ibutamoren)
- Knowing the minimal detectable dose can facilitate the interpretation of a hair test result: II. Case example with ibutamoren (MK-677), a growth hormone secretagogue.
Clinica chimica acta; international journal of clinical chemistry, 2026
- Hepatotoxicity induced by MK-677.
BMJ case reports, 2025
- Investigating the P53-dependent anti-cancer effect of ibutamoren in human cancer cell lines.
Basic & clinical pharmacology & toxicology, 2025
TB-500
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.
Joint diseases and related surgery, 2026
- Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2024
- Adsorption effects of the doping relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5.
Analytical biochemistry, 2017
Ready to Learn More?
Looking for trusted sources?